A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.
NCT ID: NCT07174024
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2025-01-20
2025-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Punch Minigraft Versus Transverse Needling or Combination of Both in Treatment of Non-Segmental Vitiligo
NCT03872804
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
NCT03199664
Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB
NCT04030988
UVA1 Phototherapy in Acral Vitiligo
NCT03378011
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
NCT04245319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients will receive NB-UVB phototherapy sessions on a Randomly selected patch
patients will receive NB-UVB phototherapy sessions on a Randomly selected patch
Narrow Band UVB Treatment
type of phototherapy
Patients will receive blue light emitting diodes phototherapy on a randomly selected patch
Patients will receive blue light emitting diodes phototherapy on a randomly selected patch
blue light emitting diode
type of diode
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Narrow Band UVB Treatment
type of phototherapy
blue light emitting diode
type of diode
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both genders.
* Subjects with stable non-segmental vitiligo (≥2 patches) acral or non-acral patches of diameter ≤ 2cm.
Exclusion Criteria
* Recent exfoliation procedures.
* Recent surgical procedures.
* Poor skin conditions including keloids.
* Hypersensitivity to light ( visible and near-infrared).
* Medications that make users more sensitive to light.
* Anticoagulant and immunosuppressive treatments.
* Gestations or breastfeeding.
* A personal or family history of skin cancer.
* Unstable vitiligo (older lesions have not progressed for the last 1 years and lack of Koebner phenomena ).
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nahla Maher Mahmoud Mahran
Lecturer of Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cairo University
Giza, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-92-2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.